RARE
Ultragenyx Pharmaceutical Inc. · Healthcare · Biotechnology
Señales de momentum (gestores comparables):
amplitud de titulares +6.7% ·
flujo de acciones -11.6% ·
nuevas posiciones netas +6.2%
— fórmula
Fragmentación de la titularidad — más titulares, participación agregada menor
Todas las cifras de propiedad: únicamente gestores 13F seguidos, posiciones en acciones ordinarias, período de referencia Q4 2024
| Trimestre | Titulares | Δ | Acciones | Valor declarado | Nuevo | Cierres |
|---|---|---|---|---|---|---|
| Q2 2026 | 97 | -7 | 59.88M | $1.99B | +8 | −14 |
| Q1 2026 | 106 | +4 | 55.54M | $1.16B | +10 | −7 |
| Q4 2025 | 102 | 0 | 62.50M | $1.44B | +1 | — |
| Q3 2025 | 19 | -1 | 45.29M | $1.36B | — | −2 |
| Q2 2025 | 18 | -1 | 33.50M | $1.22B | — | −1 |
| Q1 2025 | 16 | 0 | 17.22M | $623.52M | — | — |
| Q4 2024 | 16 | +1 | 16.41M | $690.18M | +1 | — |
| Q3 2024 | 14 | +2 | 15.84M | $879.45M | +2 | — |
| Q2 2024 | 12 | — | 15.75M | $647.24M | — | — |
| # | Gestor | Acciones | Δ acciones | Valor | Su ponderación | Mantenida | ||
|---|---|---|---|---|---|---|---|---|
| 1 | State Street Global Advisors ✦ (pasivo) | 2.72M | — | $114.54M | 0.0% | n/c | 1 | SEC ↗ |
| 2 | T. Rowe Price ✦ | 2.51M | -18.1% | $105.70M | 0.0% | ▼ Trim | 3 | SEC ↗ |
| 3 | T. Rowe Price ✦ | 2.51M | -18.1% | $105.70M | 0.0% | ▼ Trim | 3 | SEC ↗ |
| 4 | Wellington Management ✦ | 2.46M | -41.0% | $103.39M | 0.0% | ▼ Trim | 3 | SEC ↗ |
| 5 | Wellington Management ✦ | 2.46M | -41.0% | $103.39M | 0.0% | ▼ Trim | 3 | SEC ↗ |
| 6 | Wellington Management ✦ | 2.46M | -41.0% | $103.39M | 0.0% | ▼ Trim | 3 | SEC ↗ |
| 7 | Wellington Management ✦ | 2.46M | -41.0% | $103.39M | 0.0% | ▼ Trim | 3 | SEC ↗ |
| 8 | Wellington Management ✦ | 2.46M | -41.0% | $103.39M | 0.0% | ▼ Trim | 3 | SEC ↗ |
| 9 | Wellington Management ✦ | 2.46M | -41.0% | $103.39M | 0.0% | ▼ Trim | 3 | SEC ↗ |
| 10 | Geode Capital Management ✦ (pasivo) | 1.56M | -0.5% | $65.77M | 0.0% | ▼ Trim | 3 | SEC ↗ |
| 11 | Geode Capital Management ✦ (pasivo) | 1.56M | -0.5% | $65.77M | 0.0% | ▼ Trim | 3 | SEC ↗ |
| 12 | Adage Capital Partners ✦ | 1.18M | -22.5% | $49.77M | 0.1% | ▼ Trim | 3 | SEC ↗ |
| 13 | Point72 Asset Management ✦ | 1.18M | +81.0% | $49.76M | 0.1% | ▲ Add | 3 | SEC ↗ |
| 14 | Marshall Wace ✦ | 1.05M | +27.9% | $44.24M | 0.1% | ▲ Add | 3 | SEC ↗ |
| 15 | Marshall Wace ✦ | 1.05M | +27.9% | $44.24M | 0.1% | ▲ Add | 3 | SEC ↗ |
| 16 | Norges Bank ✦ (pasivo) | 961.79K | +2.2% | $40.46M | 0.0% | ▲ Add | 3 | SEC ↗ |
| 17 | Millennium Management ✦ | 697.24K | -1.9% | $29.33M | 0.0% | ▼ Trim | 3 | SEC ↗ |
| 18 | Two Sigma Investments ✦ | 614.95K | -18.6% | $25.87M | 0.1% | ▼ Trim | 3 | SEC ↗ |
| 19 | Citadel Advisors ✦ | 286.18K | +496.8% | $12.04M | 0.0% | ▲ Add | 3 | SEC ↗ |
| 20 | Citadel Advisors ✦ | 286.18K | +496.8% | $12.04M | 0.0% | ▲ Add | 3 | SEC ↗ |
| 21 | D. E. Shaw & Co. ✦ | 286.08K | +9.4% | $12.04M | 0.0% | ▲ Add | 3 | SEC ↗ |
| 22 | AQR Capital Management ✦ | 280.55K | -73.1% | $11.80M | 0.0% | ▼ Trim | 3 | SEC ↗ |
| 23 | AQR Capital Management ✦ | 280.55K | -73.1% | $11.80M | 0.0% | ▼ Trim | 3 | SEC ↗ |
| 24 | Fisher Asset Management ✦ | 265.19K | Nuevo | $11.16M | 0.0% | New | 1 | SEC ↗ |
| 25 | Renaissance Technologies ✦ | 254.70K | +39.9% | $10.72M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 26 | Duquesne Family Office ✦ | 85.44K | 0.0% | $3.60M | 0.1% | Held | 2 | SEC ↗ |
«Su ponderación» = la participación de la posición en el valor de renta variable 13F declarado por ese gestor — la medida de convicción. ✦ = gestor seleccionado.
Nuevos compradores
| Fisher Asset Management | $11.16M | 0.0% |
Posición cerrada
| Sin salidas rastreadas este trimestre. |
Contexto de mercado completo: entre TODOS los filers 13F (datos estructurados SEC, Q1 2026): 293 tenedores, 97.86M acciones, $1.96B declarado. Este es un período diferente y anterior al de las cifras del universo rastreado que figuran arriba, y ambos nunca se mezclan.
Qué otros valores suelen tener también los tenedores rastreados de este activo — recuentos de cotenencia, no relaciones fundamentales.